PharmaFocus Today – Page 399 – media

mRNA vaccine beats infection for key defense against COVID-19, Stanford Medicine scientists find

Stanford Medicine researchers have shown that prior SARS-CoV-2 infection reduces killer T cells’ response to vaccination. These cells are crucial for eliminating the virus from the body. March 28, 2023 – By Bruce Goldman T cells are more difficult to measure than antibodies, but they play a crucial role in fighting pathogens.Kateryna Kon/Shutterstock.com The Pfizer/BioNTech mRNA vaccine directed at COVID-19 is much better than natural infection at revving up key immune cells called killer T cells to fight future infection by SARS-CoV-2, the virus that causes COVID-19, Stanford Medicine investigators have found. The scientists also showed, in a study published online in Immunity, that getting infected by SARS-CoV-2 before getting vaccinated lowers the vaccine’s otherwise exceptional ability to spur proliferation and activation of killer T cells directed at SARS-CoV-2. Their finding suggests that those hoping to avoid the manifold health risks associated with COVID-19 would do well to get vaccinated before they contract ...
- Source: drugdu
- 153
- March 31, 2023
UK monkeypox vaccine rollout to wind down

The UK Health Security Agency (UKHSA) has announced its vaccination programme against mpox will end this summer. Cases of the disease have fallen from a peak of 350 per week in July to just six new cases so far in 2023, three of which were caught overseas. First doses of the vaccine will remain available to those at highest risk until 16 June, with second doses available until the end of July. The UKHSA says it will monitor cases and restart the programme if needed. While the mpox, formerly known as monkeypox, virus can infect anyone, most UK cases were among men who have sex with men. Anyone eligible who has not yet received a vaccine is being encouraged to book an appointment to protect themselves before summer. Greg Owen, from sexual health and Human Immunodeficiency Virus (HIV) charity the Terrence Higgins Trust, said: ...
- Source: drugdu
- 198
- March 30, 2023
Is Parkinson’s disease, ‘world’s fastest growing brain disease,’ mostly preventable?

Researchers warn that a colorless chemical known as trichloroethylene (TCE) — which has been used to dry-clean clothes, degrease metals and decaffeinate coffee — may be linked to the dramatic increase in Parkinson’s disease (PD) cases. They recently published a series of seven cases in the Journal of Parkinson’s disease that illustrate TCE’s harmful health effects and the potential PD association. “TCE is associated with a 500% increased risk of Parkinson’s disease,” lead author Dr. Ray Dorsey, professor of neurology at the University of Rochester in New York and author of “Ending Parkinson’s Disease,” told Fox News Digital. The chemical reproduces the features of the neurological disease in laboratory animals. It impairs the function of the energy-producing parts of cells called mitochondria, which are known to be damaged in Parkinson’s disease, Dorsey added. Widespread applications of TCE TCE was first synthesized in the lab in ...
- Source: drugdu
- 159
- March 30, 2023
‘Overwhelming’ support for regulation of vape imports amid ‘health emergency’, TGA reports

An “overwhelming” number of health experts and authorities support tightening border controls around nicotine vaping products, with many wanting an import ban on non-nicotine vaping products as well, Australia’s drugs regulator has told the government. On Thursday afternoon, the Therapeutic Goods Administration (TGA) published the almost 4,000 public submissions made in response to the government’s proposed vaping reforms, aimed at tackling rising youth vaping rates and a burgeoning black market. “All state and territory governments supported tightening border controls for nicotine vaping products, with most also supporting closing the personal importation scheme and requiring import permits,” the TGA summary said. Health professional bodies, public health associations, individual health professionals and university researchers “overwhelmingly supported tightening border controls,” the TGA said. “Many public health experts and bodies submitted that border controls should be also be placed on non-nicotine vaping products.” The importation of all vaping products should be banned “as soon ...
- Source: drugdu
- 396
- March 30, 2023
Vaccination, Paxlovid decrease risk of long Covid, studies show

People who are vaccinated or who take Paxlovid during a Covid-19 infection have a lower risk of developing long Covid, new research shows. The US Centers for Disease Control and Prevention defines long Covid as new, returning or ongoing health issues more than four weeks after an initial infection. According to the CDC, 1 in 5 Covid-19 survivors ages 18 to 64 and 1 in 4 survivors 65 or older have an ongoing health issue that might be attributable to Covid-19 infection。 A study published Thursday in JAMA Internal Medicine analyzed data from 41 studies, including more 860,000 people around the world. Of the four studies with vaccination information of nearly 250,000 people, those who had been vaccinated against Covid-19 had almost half the risk of long Covid than people who weren’t vaccinated. “These findings are important because they enable us to better understand who may develop ...
- Source: drugdu
- 139
- March 30, 2023
Royal Papworth Hospital robot for thoracic surgery to be UK first

A cutting-edge surgical robot is to be installed at the Royal Papworth Hospital in Cambridge. The Versius technology mimics human arm joints but has up to four times more rotation than the human wrist. It will be used in thoracic surgery, which includes heart and lungs, in a first for the UK. The device should make the surgery less invasive, improve outcomes and speed up patients’ recovery times, the hospital said. Staff at the hospital are to undergo a full training programme, with the first treatment due to start this spring. The technology is a partnership between the Royal Papworth and Cambridge-based company CMR Surgical. The robot is smaller than previous examples and is portable so it can be used in different theatres and for different specialities, which could include transplantation. “Our vision is to provide tomorrow’s treatment to today’s patients,” said Tim ...
- Source: drugdu
- 129
- March 30, 2023
International trade of colistin in animal feed continues unabated

In a recent study published in the journal The Lancet’s Microbe, researchers investigate Enterobacterales species resistance to colistin in Pakistan. Moreover, the researchers report on colistin import and export, use, and socioeconomic variables associated with colistin resistance. Background Studies have reported that colistin use in farming in China has driven Mcr-1-mediated resistance in Escherichia coli (MCRPEC), particularly in animal feed and prophylaxis. As a result, a ban on the agricultural use of colistin was enforced in April 2017, which reduced the prevalence of MCRPEC. However, colistin is used widely in food-producing animals in other nations for growth, prophylaxis, and treatment of colibacillosis. The spread of plasmid-mediated colistin resistance in Enterobacterales in the environment, among humans and food-producing animals has raised population health concerns. Even though colistin resistance decreased in China following its ban, colistin manufacture and export as pharmaceutical raw materials (PRMs) or feed additives continues. About the ...
- Source: drugdu
- 113
- March 30, 2023
prioritizing efficacy when considering quality of life

It is an exciting yet challenging time to be a treating physician in oncology, particularly in kidney cancer. The last decade of scientific innovation has brought an unprecedented shift in treatment options, and people now live longer than before with kidney cancer. Despite this, kidney cancers are the tenth most common cancer globally, with renal cell carcinoma (RCC) the most common type of kidney cancer, making up about 85% of diagnoses. There is no known cure for people living with advanced RCC, and the 5-year survival rate is around 12%, demonstrating the importance of continuing to find new innovative treatments. The introduction of next-generation tyrosine kinase inhibitors, immunotherapy-based agents, and, more recently, combination therapies have transformed the clinical outcomes of people living with RCC. However, with innovation comes more choice and increasingly complex therapeutic decision-making – often raising questions around the optimal sequence of treatments, particularly in more advanced ...
- Source: drugdu
- 256
- March 30, 2023
Alzheimer’s Association report highlights need to improve patient-physician communication Both individuals and primary care physicians reported a reluctance to address cognitive concerns

A new report from the Alzheimer’s Association has highlighted a need to improve patient-physician communication surrounding cognitive concerns. Following results from its 2023 Alzheimer’s Disease Facts and Figures report, the organisation said that a reluctance by the public and doctors to address memory and thinking worries hinders diagnosis and access to potential new treatments. “Providing the best possible care for Alzheimer’s disease requires conversations about memory at the earliest point of concern and a knowledgeable, accessible care team that includes physician specialists to diagnose, monitor disease progression and treat when appropriate,” said Maria Carrillo, chief science officer, Alzheimer’s Association. An accompanying report, The Patient Journey In an Era of New Treatments, also provides new insights from patients and primary care physicians (PCPs) on the current barriers to addressing cognitive concerns. Most focus group participants said their memory and thinking problems would need to have a significant ...
- Source: drugdu
- 149
- March 28, 2023
Chiesi Group and Affibody AB partner on respiratory disease treatments The companies will progress up to three programmes against undisclosed target

The Chiesi Group and Affibody AB have announced a collaboration and licensing agreement aimed at developing and commercialising innovative treatments for respiratory diseases. The partnership will see both companies utilise Affibody’s proprietary technology to progress up to three programmes against undisclosed targets for respiratory diseases. Italy-based biopharma Chiesi will fund all discovery, development and subsequent commercialisation worldwide alone, with Affibody retaining the option to co-promote in the Nordic region. The small size of Affibody’s molecules in combination with their robustness allows for the unique attributes explored under this collaboration, the companies explained, such as broad distribution and sustained exposure in the lung, as seen in preclinical models. David Bejker, chief executive officer of Affibody, said: “This collaboration with Chiesi accelerates Affibody’s strategic development and further reinforces the competitiveness of our technology which has now been validated both clinically and commercially. “We acknowledge and appreciate Chiesi’s ...
- Source: drugdu
- 138
- March 28, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.